TD Asset Management’s BridgeBio Pharma BBIO Stock Holding History

TD Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Sell	136,502 -7,678	-5%	-$557K	0.01%	638
2025 Q4	$11M	Buy	144,180 +55,230	+62%	+$3.63M	0.01%	633
2025 Q3	$4.62M	Buy	+88,950	New	+$4.34M	﹤0.01%	800
2024 Q2	–	Sell	-29,074	Closed	-$899K	–	1370
2024 Q1	$899K	Hold	29,074	–	–	﹤0.01%	1184
2023 Q4	$1.17M	Buy	+29,074	New	+$873K	﹤0.01%	1146
2021 Q3	–	Sell	-23,432	Closed	-$1.25M	–	1529
2021 Q2	$1.25M	Sell	23,432 -12,837	-35%	-$733K	﹤0.01%	1211
2021 Q1	$2.23M	Buy	+36,269	New	+$2.37M	﹤0.01%	1081

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Asset Management's BBIO Position: Q1 2026 in Review

TD Asset Management reduced its BridgeBio Pharma (BBIO) stake by 5.3% in Q1 2026, selling an estimated $557K and leaving 136,502 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #638.

TD Asset Management first reported a position in BBIO in Q1 2021 and has held it in 7 quarters since. The position peaked at $11M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

TD Asset Management held 136,502 shares of BridgeBio Pharma worth $10.1M as of Q1 2026.
TD Asset Management sold 7,678 BridgeBio Pharma shares in Q1 2026, an estimated $557K.
BridgeBio Pharma made up 0.01% of TD Asset Management's portfolio in Q1 2026, its #638 holding.
TD Asset Management first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 7 quarters since.
TD Asset Management's BridgeBio Pharma position peaked at $11M in Q4 2025.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.